Abstract #2395
The measurement of the characteristics of the metabolic syndrome and the effect of a targeted treatment of rosiglitazone
Ernst Suidgeest 1 , Bigit Den Adel 1,2 , Jos W.A. Van der Hoorn 3 , Rob E Poelmann 4 , and Louise Van der Weerd 1,5
1
Radiology, LUMC, Leiden, Netherlands,
2
Anatomy,
LUMC, Netherlands,
3
Metabolic
Health Research, TNO, Leiden, Netherlands,
4
Anatomy,
LUMC, Leiden, Netherlands,
5
Human Genetics,
LUMC, Netherlands
The objectives of this study were: 1. to establish
whether rosiglitazone administration causes cardiac
dysfunction in a mouse model. 2. to establish whether
liposome-encapsulation reduces these side effects, if
present, and 3. to investigate whether liposomal
delivery of rosiglitazone preserves the therapeutic
response compared to standard rosiglitazone. This study
shows that MRI is a tool that can be used to assess the
diverse aspects of metabolic syndrome. We showed that
rosiglitazone at a standard clinical dose induces
dilated cardiomyopathy and weight gain in the LDLr-/-
mouse model. Micelle encapsulation of rosiglitazone
significantly improves these unwanted side effects.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
